Rahman S
Brain Commun. 2025; 7(1):fcae470.
PMID: 39816196
PMC: 11733768.
DOI: 10.1093/braincomms/fcae470.
Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X
Signal Transduct Target Ther. 2025; 10(1):9.
PMID: 39788934
PMC: 11724432.
DOI: 10.1038/s41392-024-02044-3.
Kanemaru E, Ichinose F
Pharmacol Ther. 2024; 266:108787.
PMID: 39719173
PMC: 11806942.
DOI: 10.1016/j.pharmthera.2024.108787.
Huff A, Oliveira L, Karlen-Amarante M, Ebiala F, Ramirez J, Kalume F
Exp Neurol. 2024; 385:115123.
PMID: 39710245
PMC: 11781966.
DOI: 10.1016/j.expneurol.2024.115123.
Wang H, Miranda M, Marutani E, Lichtenegger P, Wojtkiewicz G, Ichinose F
J Clin Invest. 2024; 134(23).
PMID: 39621311
PMC: 11601899.
DOI: 10.1172/JCI185569.
Hypoxia-mediated rescue of retinal ganglion cells deficient in mitochondrial complex I is independent of the hypoxia-inducible factor pathway.
Warwick A, Bomze H, Wang L, Hao Y, Stinnett S, Gospe 3rd S
Sci Rep. 2024; 14(1):24114.
PMID: 39406814
PMC: 11480089.
DOI: 10.1038/s41598-024-75916-x.
Ndufs4 inactivation in glutamatergic neurons reveals swallow-breathing discoordination in a mouse model of Leigh Syndrome.
Huff A, Oliveira L, Karlen-Amarante M, Ebiala F, Ramirez J, Kalume F
bioRxiv. 2024; .
PMID: 39314482
PMC: 11419062.
DOI: 10.1101/2024.09.11.612506.
Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome.
Nakai R, Varnum S, Field R, Shi H, Giwa R, Jia W
Nat Metab. 2024; 6(10):1886-1896.
PMID: 39223312
DOI: 10.1038/s42255-024-01125-5.
Randomized controlled trial of intermittent hypoxia in Parkinson's disease: study rationale and protocol.
Janssen Daalen J, Meinders M, Mathur S, van Hees H, Ainslie P, Thijssen D
BMC Neurol. 2024; 24(1):212.
PMID: 38909201
PMC: 11193237.
DOI: 10.1186/s12883-024-03702-3.
Exclusion of sulfide:quinone oxidoreductase from mitochondria causes Leigh-like disease in mice by impairing sulfide metabolism.
Kanemaru E, Shimoda K, Marutani E, Morita M, Miranda M, Miyazaki Y
J Clin Invest. 2024; 134(15).
PMID: 38870029
PMC: 11290971.
DOI: 10.1172/JCI170994.
Monogenic Disorders of ROS Production and the Primary Anti-Oxidative Defense.
Gruning N, Ralser M
Biomolecules. 2024; 14(2).
PMID: 38397443
PMC: 10887155.
DOI: 10.3390/biom14020206.
Hypoxia Sensing and Responses in Parkinson's Disease.
Burtscher J, Duderstadt Y, Gatterer H, Burtscher M, Vozdek R, Millet G
Int J Mol Sci. 2024; 25(3).
PMID: 38339038
PMC: 10855464.
DOI: 10.3390/ijms25031759.
Challenges and opportunities to bridge translational to clinical research for personalized mitochondrial medicine.
Gropman A, Uittenbogaard M, Chiaramello A
Neurotherapeutics. 2024; 21(1):e00311.
PMID: 38266483
PMC: 10903101.
DOI: 10.1016/j.neurot.2023.e00311.
Hypoxia and intra-complex genetic suppressors rescue complex I mutants by a shared mechanism.
Meisel J, Miranda M, Skinner O, Wiesenthal P, Wellner S, Jourdain A
Cell. 2024; 187(3):659-675.e18.
PMID: 38215760
PMC: 10919891.
DOI: 10.1016/j.cell.2023.12.010.
Structural insights into respiratory complex I deficiency and assembly from the mitochondrial disease-related ndufs4 mouse.
Yin Z, Agip A, Bridges H, Hirst J
EMBO J. 2024; 43(2):225-249.
PMID: 38177503
PMC: 10897435.
DOI: 10.1038/s44318-023-00001-4.
In vivo protein turnover rates in varying oxygen tensions nominate MYBBP1A as a mediator of the hyperoxia response.
Chen X, Haribowo A, Baik A, Fossati A, Stevenson E, Chen Y
Sci Adv. 2023; 9(49):eadj4884.
PMID: 38064566
PMC: 10708181.
DOI: 10.1126/sciadv.adj4884.
Rethinking neurodegenerative diseases: neurometabolic concept linking lipid oxidation to diseases in the central nervous system.
Helgudottir S, Morkholt A, Lichota J, Bruun-Nyzell P, Andersen M, Kristensen N
Neural Regen Res. 2023; 19(7):1437-1445.
PMID: 38051885
PMC: 10883494.
DOI: 10.4103/1673-5374.387965.
Defective function of α-ketoglutarate dehydrogenase exacerbates mitochondrial ATP deficits during complex I deficiency.
Piroli G, Manuel A, McCain R, Smith H, Ozohanics O, Mellid S
Redox Biol. 2023; 67:102932.
PMID: 37883842
PMC: 10618796.
DOI: 10.1016/j.redox.2023.102932.
Reply to: Hypoxia treatment of Parkinson's disease may disrupt the circadian system.
Janssen Daalen J, Meinders M, Straatsma I, Ainslie P, Thijssen D, Bloem B
BMC Neurol. 2023; 23(1):235.
PMID: 37337147
PMC: 10280968.
DOI: 10.1186/s12883-023-03281-9.
Continuous, but not intermittent, regimens of hypoxia prevent and reverse ataxia in a murine model of Friedreich's ataxia.
Ast T, Wang H, Marutani E, Nagashima F, Malhotra R, Ichinose F
Hum Mol Genet. 2023; 32(16):2600-2610.
PMID: 37260376
PMC: 10407700.
DOI: 10.1093/hmg/ddad091.